Skip to main content
SpringerLink
Log in

Age-Related Characteristics of Sleep Impairments in a Model of the Preclinical Stage of Parkinson’s Disease in Rats

  • Published:
Neuroscience and Behavioral Physiology Aims and scope Submit manuscript

Objective. To assess changes in the time characteristics of the states of sleep and waking which may serve as nonmotor signs of the initial stage of PD using a model of the preclinical stage of Parkinson’s disease (BP) in Wistar rats of different ages. Materials and methods. A model of the prolonged (up to 21 days) preclinical stage of PD in middle-aged (6–7 months) and elderly (19–20 months) rats was created using increasing suppression of the proteasome system of the brain by intranasal administration of the specific proteasome inhibitor lactacystin. Continuous (24 h) computerized recording of polysomnograms including body temperature was performed using a Dataquest A.R.T. System telemetry system (DSI, USA) with the animals in conditions of free behavior. Results and conclusions. The results obtained here showed that aging produced a two-fold increase in sleepiness in the active (dark) period of the day and a 1.5-fold increase in the content of shallow sleep in the inactive phase. Hypersomnia in the active period of the day, comparable with excessive daytime sleepiness syndrome in humans, was identified as a sign of sleep impairment in the model of preclinical PD common to middle-aged and elderly animals. This syndrome was more marked in elderly animals, as it appeared on the background of age-related increases in sleepiness. The model of the preclinical stage of PD in middle-aged and elderly rats demonstrated reduced δ-wave activity in slow-wave sleep as a dangerous syndrome, where increasing inhibition of the proteasome system of the brain decreases the rate of protein synthesis and reduces the activity of restorative processes in nerve cells. Sleep impairments seen in the model of the preclinical stage of PD in rats of different ages can be recommended for validation in clinical trials as an early and low-cost marker for the initial stages of PD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. De Lau and M. M. Breteler, “Epidemiology of Parkinson’s disease,” Lancet Neurol., E. 5, No. 6, 525–535 (2006), https://doi.org/10.1016/S1474-4422(06)70471-9.

  2. E. Dorsey, R. Constantinescu, J. P. Thompson, et al., “Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030,” Neurology, 68, No. 5, 384–386 (2007), https://doi.org/10.1212/01.wnl.0000247740.47667.03.

  3. M. V. Ugryumov, “Translational, personalized, and preventive medicine as the basis for the fight against neurodegenerative diseases,” in: Neurodegenerative Diseases: From Genome to the Whole Organism, Scientific World Press, Moscow (2014).

  4. Yu. F. Pastukhov, “Changes in the characteristics of paradoxical sleep are an early feature of Parkinson’s disease,” Zh. Vyssh. Nerv. Deyat., 63, No. 1, 75–85 (2013), https://doi.org/10.7868/s0044467713010103.

  5. N. A. Amosova, I. G. Smolentseva, P. M. Guseinova, et al., “Sleep impairment at the early stage of Parkinson’s disease in patients not taking antiparkinson drugs,” Zh. Nevrol. Psikhiatr., 116, No. 6, 77–81 (2016), https://doi.org/10.17116/jnevro20161166277-81.

  6. J. Gomez-Esteban, B. Tijero, J. Somme, et al., “Impact of psychiatric symptoms and sleep disorders on the quality of life of patients with Parkinson’s disease,” J. Neurol., 258, No. 3, 494–499 (2010), https://doi.org/10.1007/s00415-010-5786-y.

  7. M. R. Nodel’, N. N. Yakhno, Yu. V. Ukraintseva, and V. B. Dorokhov, “Insomnia in Parkinson’s disease and its impact on patients’ quality of life,” Nevrol. Zh., 19, No. 4, 19–27 (2014), https://doi.org/10.18821/1560-9545-2014-19-4-19-27.

  8. R. B. Postuma, J. F. Gagnon, M. Vendette, et al., “Quantifying the risk of neurodegenerative disease in idiopathic REM sleep behavior disorder,” Neurology, 72, No. 15, 1296–1300 (2009), https://doi.org/10.1212/01.wnl.0000340980.19702.6e.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Yu. F. Pastukhov, I. V. Ekimova, and A. V. Chesnokova, “Molecular mechanisms of the pathogenesis of Parkinson’s disease and the prospects for preventive therapy,” in: Neurodegenerative Diseases: From Genome to the Whole Organism, M. V. Ugryumov (ed.), Nauchnyi Mir, Moscow (2014), Vol. 1.

  10. B. F. Boeve, “REM Sleep behavior disorder: Updated review of the core features, the RBD neurodegenerative disease association, evolving concepts, controversies, and future directions,” Ann. N. Y. Acad. Sci., 1184, 15–54 (2011), https://doi.org/10.1111/j.1749-6632.2009.05115.x.

  11. I. H. Hansen, M. Marcussen, J. A. Christensen, et al., “Detection of a sleep disorder predicting Parkinson’s disease,” Conf. Proc. IEEE Eng. Med. Biol. Soc., 5793–5796 (2013), https://doi.org/10.1109/embc.2013.6610868.

  12. E. Tandberg, J. Larsen, and K. Karlsen, “Excessive daytime sleepiness and sleep benefit in Parkinson’s disease: a community-based study,” Mov. Disord., 14, No. 6, 922–927 (1999), https://doi.org/10.1002/1531-8257(199911)14:6<922::aid-mds1003>3.0.co;2-7.

  13. W. G. Ondo, K. Dat Vuong, H. Khan, et al., “Daytime sleepiness and other sleep disorders in Parkinson’s disease,” Neurology, 57, No. 8, 1392–1396 (2001), https://doi.org/10.1212/wnl.57.8.1392.

  14. L. M. Chahine, A. W. Amara, and A. Videnovic, “A systematic review of the literature on disorders of sleep and wakefulness in Parkinson’s disease from 2005 to 2015,” Sleep Med. Rev., 35, 33–50 (2017), https://doi.org/10.1016/j.smrv.2016.08.001.

  15. I. Shpirer, A. Miniovitz, C. Klein, et al., “Excessive daytime sleepiness in patients with Parkinson’s disease: a polysomnography study,” Mov. Disord., 21, No. 9, 1432–1438 (2006), https://doi.org/10.1002/mds.21002.

  16. T. Simuni, C. Caspell-Garcia, C. Coffey, et al., “Correlates of excessive daytime sleepiness in de novo Parkinson’s disease: A case control study,” Mov. Disord., 30, No. 10, 1371–1381 (2015), https://doi.org/10.1002/mds.26248.

  17. R. D. Abbott, G. Ross, L. R. White, et al., “Excessive daytime sleepiness and subsequent development of Parkinson disease,” Neurology, 65, No. 9, 1442–1446 (2005), https://doi.org/10.1212/01.wnl.0000183056.89590.0d.

    Article  CAS  PubMed  Google Scholar 

  18. M. Gjerstad, D. Aarsland, and J. P. Larsen, “Development of daytime somnolence over time in Parkinson’s disease,” Neurology, 58, No. 10, 1544–1546 (2002), https://doi.org/10.1212/wnl.58.10.1544.

  19. M. A. Brodsky, J. Godbold, T. Roth, and C. W. Oanow, “Sleepiness in Parkinson’s disease: a controlled study,” Mov. Disord., 18, No. 6, 668–672 (2003), https://doi.org/10.1002/mds.10429.

  20. M. R. Nodel’, I. M. Rusakova, and N. N. Yakhno, “Clinical assessment of sleep and waking disorders in Parkinson’s disease,” Nevrol. Zh., 2, 19–25, (2010).

  21. M. R. Nodel’, “Fatigue and insomnia in Parkinson’s disease: general mechanisms and pathways of correction,” Nervnye Bolezni, No. 1, 23–26 (2015).

  22. A. Ciechanover and Y. T. Kwon, “Degradation of misfolded proteins in neurodegenerative diseases: therapeutic targets and strategies.,” Exp. Mol. Med., 47, No. 3, e147. (2015), https://doi.org/10.1038/emm.2014.117.

  23. Yu. F. Pastukhov, A. Yu. Chesnokova, A. A. Yakimchuk, et al., “Changes in sleep in degeneration of the substantia nigra induced with the proteasome inhibitor lactacystin,” Ros. Fiziol. Zh., 96, No. 12, 1190–1202 (2010), https://doi.org/10.1007/s11055-012-9578-y.

    Article  CAS  Google Scholar 

  24. I. V. Ekimova, V. V. Simonova, M. A. Guzeev, et al., “Changes in sleep characteristics in a model of Parkinson’s disease based on attenuation of the ubiquitin-proteasome system activity in the brain in rats,” Zh. Evol. Biokhim. Fiziol., 52, No. 6, 413–422 (2016), https://doi.org/10.1134/s1234567816060057.

  25. Yu. F. Pastukhov, V. V. Simonova, M. V. Chernyshev, et al., “Signs of sleep and behavior disorders indicating the initial stage of neurodegeneration in a rat model of Parkinson’s disease,” J. Evol. Biochem. Physiol., 53, No. 5, 431–434 (2017), https://doi.org/10.1134/s0022093017050106.

  26. D. V. Plaksina, M. V. Chernyshev, M. N. Karpenko, et al., “Experimental modeling of a preclinical Parkinson’s disease stage in rats by intranasal lactacystin administration,” Neurodegener. Dis., 17, Suppl. 1, 1655 (2017), https://doi.org/10.1159/000464378.

  27. D. V. Plaksina and I. V. Ekimova, “Age-related features of α-synuclein pathology in the brain on modeling the preclinical stage of Parkinson’s disease in rats,” Neurosci. Behav. Physiol., 50, No. 1, 109–114 (2020), https://doi.org/10.1007/s11055-019-00875-0.

  28. M. N. Karpenko, Z. M. Muruzheva, N. S. Pestereva, and I. V. Ekimova, “An infection hypothesis of Parkinson’s disease.,” Neurosci. Behav. Physiol., 49, No. 5, 555–561 (2019), https://doi.org/10.1007/s11055-019-00769-1.

  29. I. N. Abdurasulova, I. V. Ekimova, M. V. Chernyshev, et al., “Impairments to cognitive functions in a model of the preclinical stage of Parkinson’s disease in Wistar rats,” Zh. Vyssh. Nerv. Deyat., 69, No. 3, 364–381 (2019), https://doi.org/10.1134/S0044467719030031.

  30. I. V. Ekimova, A. R. Gazizova, M. N. Karpenko, and D. V. Plaksina, “Signs of anhedonia and destructive changes in the ventral tegmental area of the midbrain in an experimental model of the preclinical stage of Parkinson’s disease,” Zh. Nevrol. Psikhiatr., 118, No. 9, 61–67 (2018), https://doi.org/10.17116/jnevro201811809161.

  31. M. V. Chernyshev, I. V. Ekimova, A. R. Gazizova, et al., “Characteristics of emotional behavior in elderly rats in a model of the preclinical stage of Parkinson’s disease,” Zh. Evol. Biokhim. Fiziol., 54, No. 6, 444–446 (2018), https://doi.org/10.1134/S004445291806013X.

  32. H. Braak, E. Ghebremedhin, U. Rub, et al., “Stages in the development of Parkinson’s disease related pathology,” Cell Tissue Res., 318, No. 1, 121–134 (2004), https://doi.org/10.1007/s00441-004-0956-9.

  33. J. Li, M. V. Vitiello, and N. S. Gooneratne, “Sleep in normal aging.,” Sleep Med. Clin., 13, No. 1, 1–11 (2018), https://doi.org/10.1016/j.jsmc.2017.09.001.

    Article  PubMed  Google Scholar 

  34. A. Y. Chesnokova, I. V. Ekimova, and Y. F. Pastukhov, “Parkinson’s disease and aging,” Adv. Gerontol., 9, No. 2, 164–173 (2019), https://doi.org/10.1134/S2079057019020085.

  35. M. Rodriguez, C. Rodriguez-Sabate, I. Morales, et al., “Parkinson’s disease as a result of aging,” Aging Cell, 14, No. 3, 293–308 (2015), https://doi.org/10.1111/acel.12312.

  36. M. M. Ohayon, M. A. Carskadon, C. Guilleminault, and M. V. Vitiello, “Meta-analysis of quantitative sleep parameters from childhood to old age in healthy individuals: developing normative sleep values across the human lifespan,” Sleep, 27, No. 7, 1255–1273 (2004), https://doi.org/10.1093/sleep/27.7.1255.

    Article  PubMed  Google Scholar 

  37. M. R. Nodel’, K. V. Shevtsova, G. V. Kovrov, and N. N. Yakhno, “Nocturnal sleep disturbance in patients with daytime sleepiness in Parkinson s disease,” Nevrol. Neiropsikh. Psikhosom., 10, No. 4, 23–29 (2018), https://doi.org/10.14412/2074-2711-2018-4-23-29.

    Article  Google Scholar 

  38. Y. Leng, S. M. Goldman, P. M. Cawthon, et al., “Excessive daytime sleepiness, objective napping and 11-year risk of Parkinson’s disease in older men,” Int. J. Epidemiol., 47, No. 5, 1679–1686 (2018), https://doi.org/10.1093/ije/dyy098.

  39. H. Nakanishi, Y. Sun, R. K. Nakamura, et al., “Positive correlations between cerebral protein synthesis rates and deep sleep in Macaca mulatta,” Eur. J. Neurosci., 9, No. 2, 271–279 (1997), https://doi.org/10.1111/j.1460-9568.1997.tb01397.x.

  40. L. Xie, H. Kang, Q. Xu, et al., “Sleep drives metabolite clearance from the adult brain,” Science, 342, No. 6156, 373–377 (2013), https://doi.org/10.1126/science.1241224.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Sechenov Institute of Evolutionary Physiology and Biochemistry, Russian Academy of Sciences, St. Petersburg, Russia

    I. V. Ekimova, M. A. Guzeev, V. V. Simonova & Yu. F. Pastukhov

Authors
  1. I. V. Ekimova
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. A. Guzeev
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. V. V. Simonova
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yu. F. Pastukhov
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to I. V. Ekimova.

Additional information

Translated from Zhurnal Nevrologii i Psikhiatrii imeni S. S. Korsakova, Vol. 120, No. 9, Iss. 2, Insomnia, pp. 26–33, September, 2020.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ekimova, I.V., Guzeev, M.A., Simonova, V.V. et al. Age-Related Characteristics of Sleep Impairments in a Model of the Preclinical Stage of Parkinson’s Disease in Rats. Neurosci Behav Physi 51, 704–710 (2021). https://doi.org/10.1007/s11055-021-01124-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11055-021-01124-z

Keywords

Search

Navigation